医学教育

订阅

MedSci主页 / 所有栏目 / 医学教育

常用药物配伍禁忌，你不可不知！

2018-12-26 佚名 药圈网

药物
关注

这么多配伍禁忌的药物，你知道几个？





















评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085395, encodeId=41eb208539514, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 26 21:39:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942404, encodeId=0bde19424040b, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 09 11:39:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366656, encodeId=906236665691, content=依据是哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44895106113, createdName=14604fddm34暂无昵称, createdTime=Thu May 23 17:04:44 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545112, encodeId=9b28154511206, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619215, encodeId=c3431619215f5, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356486, encodeId=78c7356486fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 23:56:46 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356482, encodeId=17a53564827d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 21:50:43 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2019-09-26 一闲

    #常用药物#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2085395, encodeId=41eb208539514, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 26 21:39:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942404, encodeId=0bde19424040b, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 09 11:39:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366656, encodeId=906236665691, content=依据是哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44895106113, createdName=14604fddm34暂无昵称, createdTime=Thu May 23 17:04:44 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545112, encodeId=9b28154511206, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619215, encodeId=c3431619215f5, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356486, encodeId=78c7356486fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 23:56:46 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356482, encodeId=17a53564827d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 21:50:43 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2019-07-09 zgwhgch

    #配伍禁忌#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2085395, encodeId=41eb208539514, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 26 21:39:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942404, encodeId=0bde19424040b, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 09 11:39:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366656, encodeId=906236665691, content=依据是哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44895106113, createdName=14604fddm34暂无昵称, createdTime=Thu May 23 17:04:44 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545112, encodeId=9b28154511206, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619215, encodeId=c3431619215f5, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356486, encodeId=78c7356486fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 23:56:46 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356482, encodeId=17a53564827d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 21:50:43 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2019-05-23 14604fddm34暂无昵称

    依据是哪里

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2085395, encodeId=41eb208539514, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 26 21:39:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942404, encodeId=0bde19424040b, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 09 11:39:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366656, encodeId=906236665691, content=依据是哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44895106113, createdName=14604fddm34暂无昵称, createdTime=Thu May 23 17:04:44 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545112, encodeId=9b28154511206, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619215, encodeId=c3431619215f5, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356486, encodeId=78c7356486fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 23:56:46 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356482, encodeId=17a53564827d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 21:50:43 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2018-12-28 医者仁心

    #禁忌#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2085395, encodeId=41eb208539514, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 26 21:39:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942404, encodeId=0bde19424040b, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 09 11:39:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366656, encodeId=906236665691, content=依据是哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44895106113, createdName=14604fddm34暂无昵称, createdTime=Thu May 23 17:04:44 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545112, encodeId=9b28154511206, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619215, encodeId=c3431619215f5, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356486, encodeId=78c7356486fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 23:56:46 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356482, encodeId=17a53564827d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 21:50:43 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2018-12-28 docwu2019

    #常用药#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2085395, encodeId=41eb208539514, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 26 21:39:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942404, encodeId=0bde19424040b, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 09 11:39:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366656, encodeId=906236665691, content=依据是哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44895106113, createdName=14604fddm34暂无昵称, createdTime=Thu May 23 17:04:44 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545112, encodeId=9b28154511206, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619215, encodeId=c3431619215f5, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356486, encodeId=78c7356486fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 23:56:46 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356482, encodeId=17a53564827d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 21:50:43 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2018-12-26 医者仁心5538

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2085395, encodeId=41eb208539514, content=<a href='/topic/show?id=70f14863158' target=_blank style='color:#2F92EE;'>#常用药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48631, encryptionId=70f14863158, topicName=常用药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Sep 26 21:39:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942404, encodeId=0bde19424040b, content=<a href='/topic/show?id=c96d9543365' target=_blank style='color:#2F92EE;'>#配伍禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95433, encryptionId=c96d9543365, topicName=配伍禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 09 11:39:00 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366656, encodeId=906236665691, content=依据是哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44895106113, createdName=14604fddm34暂无昵称, createdTime=Thu May 23 17:04:44 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545112, encodeId=9b28154511206, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619215, encodeId=c3431619215f5, content=<a href='/topic/show?id=049148630cb' target=_blank style='color:#2F92EE;'>#常用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48630, encryptionId=049148630cb, topicName=常用药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Dec 28 12:39:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356486, encodeId=78c7356486fa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 23:56:46 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356482, encodeId=17a53564827d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Dec 26 21:50:43 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2018-12-26 医者仁心5538

    学习了

    0

相关资讯

国际多中心药物临床试验指南（试行）

国家食品药品监督管理总局2015年第2号一、背景　　近年来，药物研发日益趋于全球化，用于药品注册的国际多中心药物临床试验，已经从人用药品注册技术要求国际协调会(ICH)区域拓展到非ICH区域。药物全球同步研发，是一种共享资源的开发模式，可以减少不必要的重复临床试验，缩短区域或国家间药品上市延迟，提高患者获得新药的可及性。境内申办者为融入国际市场，也越来越关注全球同步研发。　　申办者要根据早期研

英国《每日邮报》：痤疮药物可造成早期阳痿

据英国《每日邮报》报道，痤疮药物如罗可坦胶囊可能造成永久性功能障碍的隐性流行病，即造成年轻男性早期阳痿。

广州一患者参加药物临床实验后死亡，医院研究方应如何担责？

新技术的出现总是伴随着机遇和风险。药物临床试验一直是社会敏感话题，且同时涉及多项法律适用问题。临床药物试验的申办者与受试者之间有何种法律关系？发生与试验相关的损害或死亡的情况又该如何赔偿？请一起走进今天的广州案例。基本案情阿贤和阿顺为夫妻关系，阿勇是阿贤、阿顺之子。2012年8月18日6时30分，阿顺因“言语不清1小时，伴左侧肢体乏力”送至某医院急诊。入院诊断为：？ 脑血栓形成（右侧颈内动脉系

妊娠期用药须谨慎，这些要点不可不知！

一般来讲，妊娠期母体的血浆白蛋白会因为血容量的扩大而降低，从而导致结合药物的游离浓度增大，其通过胎盘进入胎儿的游离浓度增大，加之胎儿血浆蛋白含量低，故胎儿血中游离的药物浓度约为成人的 1.2-2.4 倍。

药物防艾还需普及 很多人不知道的防艾“后悔药”

HIV阻断药，也称暴露后预防用药，英文名称PEP。在发生高危暴露行为72小时内，它可帮助人们有效阻止HIV病毒感染。

是药三分毒，安全用药听听专家怎么说

老话，人吃五谷杂粮没有不生病的，而生病最常见的治疗就是使用药物。也还有一句老话，凡药三分毒。那么，如何安全用药，不仅医务工作者要谨慎，患者同样要谨慎。